TP53 p.R337H Germline Variant among Women at Risk of Hereditary Breast Cancer in a Public Health System of Midwest Brazil
Authors:
- Tatiana Strava CorrêaTCTatiana Strava Corrêa
- Paula Fontes AsprinoPAPaula Fontes Asprino
- Eduarda Sabá Cordeiro de OliveiraEOEduarda Sabá Cordeiro de Oliveira
- Ana Carolina Rathsam LeiteALAna Carolina Rathsam Leite
- Luiza WeisLWLuiza Weis
- Maria Isabel AchatzMAMaria Isabel Achatz
- Claudiner Pereira de OliveiraCOClaudiner Pereira de Oliveira
- Renata Lazari SandovalRSRenata Lazari Sandoval
- Romualdo Barroso-SousaRBRomualdo Barroso-Sousa
Open Access
Abstract
Despite the high prevalence of TP53 pathogenic variants (PV) carriers in the South and Southeast regions of Brazil, germline genetic testing for hereditary breast cancer (HBC) is not available in the Brazilian public health system, and the prevalence of Li-Fraumeni syndrome (LFS) is not well established in other regions of Brazil. We assessed the occurrence of TP53 p.R337H carriers among women treated for breast cancer (BC) between January 2021 and January 2022 at public hospitals of Brasilia, DF, Brazil. A total of 180 patients who met at least one of the NCCN criteria for HBC underwent germline testing; 44.4% performed out-of-pocket germline multigene panel testing, and 55.6% were tested for the p.R337H variant by allelic discrimination PCR. The median age at BC diagnosis was 43.5 years, 93% had invasive ductal carcinoma, 50% had estrogen receptor-positive/HER2 negative tumors, and 41% and 11% were diagnosed respectively at stage III and IV. Two patients (1.11%) harbored the p.R337H variant, and cascade family testing identified 20 additional carriers. The TP53 p.R337H detection rate was lower than that reported in other studies from south/southeast Brazil. Nonetheless, identifying TP53 PV carriers through genetic testing in the Brazilian public health system could guide cancer treatment and prevention.Keywords
Funding Information
- Stand Up to Cancer (SU2C)
- The Instituto de Ensino e Pesquisa do Hospital Sirio-Libanes (IEP-HSL)
This publication has 26 references indexed in Scilit:
- Cancer surveillance for patients with Li-Fraumeni Syndrome in Brazil: A cost-effectiveness analysisThe Lancet Regional Health - Americas, 2022
- Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast BrazilBreast Cancer Research and Treatment, 2022
- Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data SetJAMA Oncology, 2021
- Medical guidelines for Li–Fraumeni syndrome 2019, version 1.1International Journal of Clinical Oncology, 2021
- What 20 years of research has taught us about the TP53 p.R337H mutationCancer, 2020
- Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort studyThe Breast, 2019
- A portrait of germline mutation in Brazilian at-risk for hereditary breast cancerBreast Cancer Research and Treatment, 2018
- Detailed haplotype analysis at theTP53locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effectHuman Mutation, 2009
- Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern BrazilCancer Letters, 2008
- The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian familiesCancer Letters, 2007